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Impulse control disorders (ICDs), including disordered gambling, can occur in a significant
number of patients with Parkinson’s disease (PD) receiving dopaminergic therapy.The neu-
robiology underlying susceptibility to such problems is unclear, but risk likely results from an
interaction between dopaminergic medication and a pre-existing trait vulnerability. Impulse
control and addictive disorders form part of a broader psychopathological spectrum of dis-
orders, which share a common underlying genetic vulnerability, referred to as externalizing.
The broad externalizing risk factor is a continuously varying trait reflecting vulnerability to
various impulse control problems, manifested at the overt level by disinhibitory symptoms
and at the personality level by antecedent traits such as impulsivity and novelty/sensation
seeking.Trait “disinhibition” is thus a core endophenotype of ICDs, and a key target for neu-
robiological investigation. The ventral striatal dopamine system has been hypothesized to
underlie individual variation in behavioral disinhibition. Here, we examined whether individ-
ual differences in ventral striatal dopamine synthesis capacity predicted individual variation
in disinhibitory temperament traits in individuals with PD. Eighteen early-stage male PD
patients underwent 6-[18F]Fluoro-l-DOPA (FDOPA) positron emission tomography scanning
to measure striatal dopamine synthesis capacity, and completed a measure of disinhibited
personality. Consistent with our predictions, we found that levels of ventral, but not dor-
sal, striatal dopamine synthesis capacity predicted disinhibited personality, particularly a
propensity for financial extravagance. Our results are consistent with recent preclinical
models of vulnerability to behavioral disinhibition and addiction proneness, and provide
novel insights into the neurobiology of potential vulnerability to impulse control problems
in PD and other disorders.
Keywords: dopa decarboxylase, dopamine, disordered gambling, externalizing, impulse control disorders, impul-
sivity, reward, ventral striatum
INTRODUCTION
Several addictive and impulse control disorders (ICDs) have been
associated with Parkinson’s disease (PD) and its treatment with
dopaminergic medication, including disordered gambling (Gal-
lagher et al., 2007), substance dependence (Bienfait et al., 2010),
and the addiction-like excessive use of dopaminergic medica-
tions, or DA dysregulation syndrome (Lawrence et al., 2003).
The prevalence of ICDs in medicated PD patients was estimated
at ∼14% in a large (n> 3000) multicentre study, with >25%
of affected individuals having multiple ICDs (Weintraub et al.,
2010). The development of ICDs in PD likely results from an
interaction between dopaminergic medication and an underly-
ing vulnerability, rather than from PD itself, since: (a) only a
(substantial) minority of medicated PD patients develop ICDs
(Weintraub et al., 2010); (b) ICDs are no more frequent in
patients with de novo PD than in the general population (Wein-
traub et al., 2013); (c) ICDs can develop in non-PD individ-
uals treated with dopaminergic medication (O’Sullivan et al.,
2010; Voon et al., 2011a); and (d) a family history of gambling
problems is a risk factor for the development of dopaminergic
medication-linked ICDs (Weintraub et al., 2010; Voon et al.,
2011a).
This precursive ICD vulnerability likely reflects variation in pre-
existing temperament/personality (Dagher and Robbins, 2009),
in particular, variation in the broad temperament dimension of
trait disinhibition (vs. constraint), encompassing impulsivity, nov-
elty/sensation seeking, non-planning, low self-control, and related
constructs (Markon et al., 2005). In PD, just as in non-PD popula-
tions (Sher and Trull, 1994; MacLaren et al., 2011), phenotypic
associations between trait disinhibition and substance use and
ICDs (and their comorbidity) have been repeatedly demonstrated
(Evans et al., 2005; Voon et al., 2011b).
These findings suggest etiologic similarities between ICDs
and addictions in PD and the broader domain of externalizing
(EXT) psychopathology in non-PD populations (Krueger et al.,
2007). Patterns of phenotypic, environmental, and genetic rela-
tions among DSM-defined substance misuse and antisocial disor-
ders are best accounted for by models positing a shared broad EXT
factor or vulnerability (Krueger et al., 2007). I.e., putatively dis-
tinct disorders are better understood as variants within a broader
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EXT spectrum of disorders, and the reason they systematically
co-occur is because they share a common underlying genetic vul-
nerability (Krueger et al., 2007). This broad EXT vulnerability
is a continuously distributed dimension of risk (Krueger et al.,
2007). Hierarchical models of the EXT spectrum (Krueger et al.,
2007) posit a general factor linking all EXT syndromes, as well as
distinct etiological factors that differentiate among distinct EXT
syndromes. Disordered gambling, frequently comorbid with sub-
stance abuse and antisocial personality disorder (Kessler et al.,
2008) is also considered one variant of EXT (Oleski et al., 2011;
Blanco et al., 2012; Forbush and Watson, 2013; but see Slutske
et al., 2013).
A shared genetic diathesis underlies the phenotypic associa-
tions between EXT disorders and disinhibited personality traits,
including novelty seeking (NS; Young et al., 2000; Agrawal et al.,
2004). Furthermore, prospective studies suggest that high levels
of these traits in childhood and adolescence predate and predict
the emergence of EXT psychopathology in adulthood (Sher et al.,
2000; Slutske et al., 2012). I.e., the temperamental antecedent of
disinhibition provides the core endophenotype of EXT disorders
(Clark, 2005), mediating their systematic co-variation (Khan et al.,
2005). Hence, understanding the genetics and neurobiology of
disinhibitory personality traits is critical to understanding EXT
psychopathology, including its manifestation in the context of PD
and its treatment with DA replacement therapies.
The DA system has frequently been hypothesized to underlie
individual variation in trait disinhibition. According to one promi-
nent model (Pickering and Gray, 1999), individual differences
along this temperament dimension are argued to reflect variation
in the reactivity of a neural behavioral activation system (BAS),
centered on the ventral striatum (VS), and its dopaminergic irriga-
tion,activated by cues for reward. Similarly, according to Cloninger
(1987), the disinhibitory temperament trait of NS reflects genet-
ically determined variation in dopaminergically mediated BAS
reactivity. When activated, the BAS can be characterized as an
impulsive “go” system that activates on-going appetitive behavior
(Pine et al., 2010).
Research is accumulating to suggest that variation in the DA
synthesis pathway in particular plays a key role in the etiology
of EXT. DA synthesis occurs within DA neurons. Tyrosine is
transported into the cell via amino acid carriers in the blood-
brain barrier and cell membranes. Once in the intracellular space
it is hydroxylated to l-3,4-dihydroxiphenylalanine (l-DOPA) by
tyrosine hydroxylase (TH). l-DOPA is then decarboxylated by aro-
matic l-amino acid decarboxylase [AADC; also known as dopa
decarboxylase (DDC)] to DA (Elsworth and Roth, 2009). Vari-
ants [single nucleotide polymorphisms (SNPs)] in the DDC gene
have been associated with nicotine (Ma et al., 2005; Yu et al., 2006;
Zhang et al., 2006), alcohol (Agrawal et al., 2011; Kristjansson
et al., 2012) and illicit drug (Hack et al., 2011) misuse, and most
recently, disordered gambling (Lind et al., 2012). Importantly, Der-
ringer et al. (2010) found that a combination of multiple SNPs in
the DDC gene predicted individual variation in sensation seeking
traits, suggesting that genetic variation in DA synthesis is related
to broad EXT risk.
Positron Emission Tomography (PET) can be used to study
the activity of AADC/DDC in pre-synaptic DA terminals in the
living brain. The PET tracer 6-[18F]fluoro-l-DOPA (FDOPA),
a radioactive analog of l-DOPA, the precursor of DA, is taken
up by pre-synaptic dopaminergic neurons and is metabolized
by AADC/DDC to 18F-DA, which is trapped and stored within
vesicles in the nerve terminals (Kumakura and Cumming, 2009).
FDOPA uptake, quantified as the influx constant K I, can be used
as a measure of AADC/DDC activity and vesicular storage capac-
ity (Brown et al., 1999). High values for FDOPA K I are observed
in areas of dense DA nerve terminal innervation, such as the stria-
tum, and FDOPA has been extensively used to probe the functional
integrity of striatal dopaminergic neurons in PD (Brooks, 2010)
where uptake correlates with the number of surviving nigrostri-
atal cell numbers (Snow et al., 1993). Notably, FDOPA studies in
non-PD populations have shown relatively increased striatal K I
values in alcohol (Tiihonen et al., 1998) and nicotine (Salokangas
et al., 2000) dependent individuals, although those early studies
did not measure disinhibitory personality traits, and could not
resolve dorsal and ventral striatal regions. Further, Laakso et al.
(2005) found increased striatal FDOPA uptake in A1+ allele car-
riers of the Taq1A polymorphism of the TTC12-ANKK1-DRD2
gene cluster, variation in which has been linked with EXT risk
(Ducci et al., 2011).
Collectively, the research outlined above suggests that individ-
ual variation in DA synthesis capacity, particularly in the VS,
underpins individual variation in trait disinhibition. Here, we
tested the hypothesis that increased FDOPA uptake in VS, which is
relatively spared in PD (Kish et al., 1988), would predict increased
trait disinhibition or general EXT risk, in the context of PD.
MATERIALS AND METHODS
PATIENTS
We studied 18 men with early-stage (symptom duration<2 years)
idiopathic PD based on UK PD Society Brain Bank diagnostic
criteria. Table 1 summarizes their clinical characteristics. Disease
severity was rated with the Unified Parkinson’s Disease Rating
Scale (UPDRS) motor subscale while in an “off” condition with-
drawn from medication before PET. Assessment of trait disinhi-
bition, as well as PET scanning, was performed in a practically
defined off state. Patients with pronounced tremor that would
have produced difficulty with PET imaging, as well as patients with
comorbid psychiatric or systemic physical illness were excluded.
This cohort of 18 patients was drawn from a larger group of 186
PD patients that formed the multicentre REAL-PET investigation
enrolled population. Drug escalation, tablet frequency, dose, and
UPDRS motor response to medication have been described previ-
ously (Whone et al., 2003b). At the time of PET scanning, patients
had only been started on dopaminergic medication within the
Table 1 | Patient characteristics.
Parkinson’s disease
patients (n=18)
Gender (male/female) 18/0
Age (years, mean±SD, range) 64±7, range 47–76
UPDRS motor in “off” (mean±SD) 14.6±6.5
GDS Depression (mean±SD) 9.8±8.9
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previous 4–12 weeks, and were receiving low doses of either l-
DOPA (between 300 mg to a maximum daily dose of ∼400 mg
at time of PET) or a DA agonist (between 3 mg of ropinirole
to a maximum daily dose of ∼8 mg at time of PET). Patients
were administered the 30-item Geriatric Depression Scale (GDS),
validated for use in PD (Ertan et al., 2005).
The study was limited to men for several reasons. Firstly, ICDs
and addictions in PD are more prevalent in males than females
(Weintraub et al., 2010), as they are in non-PD populations (Eaton
et al., 2012). Secondly, there are sex differences in DA synthesis
capacity (Laakso et al., 2002). Thirdly, genetic factors for NS are
excellent markers for EXT tendencies in males, but not females
(Agrawal et al., 2004; Pitzer et al., 2007), although it is unclear
whether this sex difference is an artifact of the manner in which
males and females interpret the NS construct or whether there
are true differences in the magnitude of genetic influence across
males and females. It will be important in future studies to include
females with PD.
Permission to undertake the study was granted by the Ethics
Committee of Hammersmith, Queen Charlotte’s & Chelsea, and
Acton Hospital Trust and all participants gave written informed
consent following a full explanation of the procedure, in accor-
dance with the declaration of Helsinki. The Administration of
Radioactive Substances Advisory Committee (ARSAC) of the UK
approved radioisotope use.
MEASUREMENT OF TRAIT DISINHIBITION (VS. CONSTRAINT)
Our measure of trait disinhibition (vs. constraint) was based
on NS from Cloninger’s Tri-dimensional Personality Question-
naire (TPQ; Cloninger, 1987). The version of the TPQ used
here was a 100-item, self-administered, true-false instrument. The
questionnaire is scored so that higher scores reflect greater NS.
As originally constructed (Cloninger, 1987) TPQ-NS com-
prised four narrow facet-level scales: Exploratory Excitability vs.
Stoic Rigidity (NS1), Impulsiveness vs. Reflection (NS2), Extrav-
agance vs. Reserve (NS3), and Disorderliness vs. Regimentation
(NS4). When Ando et al. (2004), however, examined the genetic
and environmental factor structure of NS, factor analysis of the
genetic inter-correlations yielded factors that did not fully resem-
ble the phenotypic structure of NS as proposed by Cloninger
(1987). NS was revised (r-NS) to consist of Impulsiveness vs.
Reflection (NS2), Extravagance vs. Reserve (NS3) and Disorderli-
ness vs. Regimentation (NS4), excluding Exploratory Excitability
vs. Stoic Rigidity (NS1). Further, Flory et al. (2006), using fac-
tor analysis in a large normative sample of middle-aged adults,
found Impulsiveness vs. Reflection (NS2) and Extravagance vs.
Reserve (NS3) to have high loadings on a “non-planning impul-
sivity” factor, together with the Barratt Impulsiveness Scale (BIS),
whereas Exploratory Excitability vs. Stoic Rigidity (NS1) loaded on
a distinct “Openness to Experience” factor, and Disorderliness vs.
Regimentation (NS4) failed to load strongly on any single factor.
Hence, in the current study, we focused on those r-NS facets most
strongly linked to trait disinhibition: Impulsiveness (vs. Reflec-
tion; NS2; eight items) and Extravagance (vs. Reserve; NS3; seven
items). Sample items include “I often react so strongly to unexpected
news that I say or do things that I regret,” “I often have to change my
decisions because I had a wrong hunch or mistaken first impression”
(Impulsivity, NS2) and “I often spend money until I run out of cash
or get into debt from using too much credit,”“Because I so often spend
too much money on impulse, it is hard for me to save money – even
for special plans like a vacation” (Extravagance, NS3).
PET SCANNING PROTOCOL
Patients stopped medication at least 12 h prior to scanning. All
participants underwent three-dimensional FDOPA PET using an
ECAT EXACT HR++ (CTI/Siemens 966) camera, which covers
an axial field of view of 23.4 cm and provides 95 transaxial planes.
The tomograph has a spatial resolution of 4.8+ 0.2 mm FWHM
(transaxial, 1 cm off axis) and 5.6+ 0.5 mm (axial, on axis) after
image reconstruction (Spinks et al., 2000). A transmission scan,
which corrects for attenuation of emitted radiation by skull and
tissues, was acquired using a single rotating photon point source
of 150 MBq of 137Cs. Thirty seconds after the start of the emis-
sion scan, 110 MBq of FDOPA in 10 ml normal saline was infused
intravenously over 30 s. Three-dimensional sinograms of emission
data were then acquired over 94 min as 26 time frames. Patients
were placed in the scanner, orientated parallel to the orbito-metal
line and head positioning was monitored throughout the scan.
IMAGE QUANTIFICATION
Parametric images of specific FDOPA uptake (KI maps) were cre-
ated at a voxel level for the whole brain using the Patlak graphical
approach (Patlak and Blasberg, 1985) with a cerebellar cortex ref-
erence input function (Moore et al., 2003). Qualitative summated
images created from the dynamic FDOPA time series by inte-
grating all 26 frames of the dynamic image were also produced
and then transformed into standard stereotaxic [Montreal Neuro-
logical Institute (MNI)] space using an FDOPA template created
in-house from a healthy volunteer database. These so-called ADD
images contain both tracer delivery and specific uptake informa-
tion and provide adequate anatomical detail to allow stereotaxic
manipulations. Subsequently, the KI maps were also individually
normalized to MNI stereotaxic space by applying the transfor-
mation parameters defined during the normalization of their
respective ADD image. This spatial transformation of paramet-
ric images made it possible to perform a region of interest (ROI)
analysis as described below.
REGION OF INTEREST ANALYSIS
An ROI analysis was performed using a fixed object map tem-
plate after stereotaxic transformation of all images into standard
(MNI) space. This approach effectively normalizes brain position
and shape and so avoids variability of regions due to head size
and position and subjective free hand definition. Standard ROI
object maps that outlined the left and right hemisphere VS, cau-
date, and putamen were defined on the MNI single-subject ROI in
stereotaxic space (Moore et al., 2003, 2008). The standard object
map was placed onto the transformed KI maps, and values for spe-
cific FDOPA uptake were obtained for each region (see Figure 1
for ROIs). When performing our ROI analysis a manual correc-
tion for head movement was employed as described previously
(Whone et al., 2003a).
To limit the number of comparisons, and because of our spe-
cific a priori hypothesis, K I values (units: ml g−1 min−1) for the
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FIGURE 1 |The figure shows in (A) an FDOPA ADD (summed) and
net influx rate constant (K I) image of a single slice from a healthy
individual (top panels) and a patient with PD (bottom panels). In
these images normalization to (MNI) space has been performed.
Asymmetric decreased putamen and caudate uptake can be seen in
the patient with PD. In (B) the figure shows; a template region object
map overlying: the putamen and caudate nucleus bilaterally in a
normalized FDOPA ADD image from a PD patient; the FDOPA template
(created from five healthy controls) and the canonical single-subject T1
MRI found in SPM 99. (C) Shows the template object map, with
volumes shaded, for the ventral striatum and caudate nucleus overlain
on the canonical single-subject T1 MRI in sagittal section and next to it
a spatially normalized KI image in sagittal section with the ventral
striatum and caudate nucleus object map overlain. Also shown is a
spatially normalized coronal section KI map through the ventral striatum
with the object map overlain.
caudate and putamen ROIs were averaged to form left and right
dorsal striatum (DS) ROIs. Exploratory data analysis revealed that
K I and NS data were normally distributed, and so we examined
the relation between them using Pearson’s correlation coefficient.
Statistical significance was set at p< 0.01.
RESULTS
Mean± SD scores in our PD sample for NS2 (Impulsivity) and
NS3 (Extravagance) were 3.1± 1.6 and 3.1± 1.7, respectively.
Whilst population norms for individual NS facets are unavail-
able, the total NS score (NS1+NS2+NS3+NS4) of the current
PD sample (13.6± 4) was comparable to that published for age-
matched healthy male controls (n> 1000; mean age 67± 8; total
NS= 11.6± 5; Stallings et al., 1996). Mean± SD FDOPA K I val-
ues for left and right VS and left and right DS are reported in
Table 2.
In line with our a priori hypothesis, we found a significant cor-
relation between NS3 (Extravagance) scores and left VS FDOPA K I
values [r (16)= 0.61, p= 0.008, 95% CI 0.20 – 0.83; Figure 2]. This
relationship was unchanged when controlling for both age and
GDS depression scores (r = 0.63, p= 0.009). There was a similar
Table 2 | FDOPA K I values in regions of interest.
Region FDOPA K I values
(mean±SD)
Left ventral striatum 0.0127±0.0015
Right ventral striatum 0.0120±0.0014
Left dorsal striatum 0.0115±0.0018
Right dorsal striatum 0.0108±0.0015
trend in the right VS that failed to reach our pre-specified level of
statistical significance (r = 0.53, p= 0.026). (An additional analy-
sis revealed that the slightly greater correlation between left VS
FDOPA K I and NS3 was not a result of asymmetry of Parkinson-
ian symptoms). Furthermore, neither left (r =−0.13, p= 0.60)
nor right (r =−0.22, p= 0.38) VS FDOPA K I values correlated
with UPDRS motor scores. There was no significant relation
between DS FDOPA K I values and NS3 scores, although the cor-
relation with right DS values trended toward significance (left,
r = 0.27, p= 0.27; right, r = 0.41, p= 0.09). Importantly, however,
the correlation between left VS FDOPA K I values and NS3 scores
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FIGURE 2 | Scatter plot (and line of best fit) showing the relation
between trait disinhibition (NS3, Extravagance vs. reserve) and ventral
striatal dopamine synthesis capacity (FDOPA K I) in Parkinson’s
disease.
was significantly greater than that between either left [t = 2.59, p
(1-tail)= 0.01] or right [t = 1.46, p (1-tail)= 0.08] DS FDOPA K I
values and NS3 scores.
Against our hypothesis, however, there was no significant cor-
relation between NS2 (Impulsivity) scores and VS FDOPA K I
values (left, r = 0.08, p= 0.77; right, r = 0.30, p= 0.22). Nor was
there a significant correlation between NS2 scores and DS K I
values (left, r =−0.12, p= 0.65; right, r = 0.22, p= 0.37). The
correlation between left VS FDOPA K I values and NS3 (Extrav-
agance) scores was significantly greater than that between left
VS FDOPA K I values and NS2 (Impulsivity) scores [t = 2.67, p
(1-tail)= 0.008].
DISCUSSION
Our findings provide new insights into the neurobiology of poten-
tial vulnerability to impulse control problems in PD. Consistent
with our hypothesis, we found that variation in trait disinhibition
(vs. constraint), a continuously varying endophenotype for EXT
or impulse-control psychopathology, was associated with levels of
DA synthesis capacity in the VS. Individuals with higher levels of
trait disinhibition, in particular, tendencies to financial irrespon-
sibility and extravagance, had greater DA synthesis capacity, as
indexed by FDOPA K I values in the left (and to a lesser extent,
right) ventral, but not dorsal, striatum.
Although ICDs in PD have to date been treated as categori-
cal (present/absent) disorders, it is now widely accepted that such
disorders do not delineate highly discrete and easily distinguished
categories. Rather, they delineate continuous, normally distrib-
uted underlying propensities to experience psychopathology, with
personality traits linked to behavioral disinhibition forming the
core of an EXT spectrum (Clark, 2005; Krueger et al., 2007). I.e.,
psychopathology represents the extremes of continuously distrib-
uted temperament traits. This general temperamental propensity
to EXT, rather than its manifestations in particular disorders is
therefore a key focus for etiological investigations.
Whilst a recent study linked genetic variation in DDC activity
to an EXT endophenotype (sensation seeking) in healthy individ-
uals (Derringer et al., 2010), and sensation seeking has been linked
to increased ventral striatal BOLD-fMRI response during reward
anticipation (Bjork et al., 2008; see also Yau et al., 2012), ours
is the first demonstration that variation in trait disinhibition is
linked to variation in DDC activity in the VS in PD, an important
brain region underlying inter-individual variation in behavioral
disinhibition in preclinical models (Dalley et al., 2011).
We found that only the r-NS subscale NS3 (Extravagance vs.
Reserve) was related to ventral striatal DA synthesis capacity. There
was no such relation with the NS2 subscale (Impulsivity vs. Reflec-
tion), despite the relatively high correlation between NS2 and NS3
(r = 0.45). Both subscales showed a similar range of variation in
our PD sample, suggesting this is not the reason for a lack of
correlation between NS2 scores and VS FDOPA K I values. NS3
appears more trait-like (evidenced by much higher test-rest corre-
lation) than NS2 (Takeuchi et al., 2011), and appears to index those
traits (irresponsibility, inability to approach life planfully) most
strongly linked to general EXT risk (Krueger and South, 2009).
It is particularly notable that only NS3 correlates with impaired
decision-making on the Iowa Gambling Task (Álvarez-Moya et al.,
2011), which has been linked to increased VS FDOPA K I values
(Schlagenhauf et al., 2012).
On first glance, our results appear inconsistent with an earlier
study that failed to find a correlation between trait NS and VS
FDOPA K I values in unmedicated male PD patients (Kaasinen
et al., 2001). However, that study used the total NS score from the
original NS scales described by Cloninger (1987), and it is now
clear (Ando et al., 2004) that the genetic and environmental factor
structure of NS does not resemble the phenotypic structure of NS
as originally proposed, making interpretation of that previous null
result difficult.
FDOPA is not a specific ligand for DA neurons but rather is
trapped by all neurons that contain DDC (Brown et al., 1999).
Hence, it is a marker for all tissues that take up and store
monoamines, including serotonin (5-HT) as well as DA neu-
rons (Tison et al., 1991). 5-HT has also been implicated in var-
ious aspects of impulsivity (Winstanley et al., 2005; Miyazaki
et al., 2011). However, post hoc analysis of a midbrain raphe
ROI (Moore et al., 2008), a structure in which FDOPA is a
validated marker of serotonergic function in PD (Pavese et al.,
2012), in our sample, found no significant correlation between
FDOPA K I values in the raphe and either NS2 (Impulsivity)
or NS3 (Extravagance) scores (r = 0.11, p= 0.67 and r = 0.32,
p= 0.2, respectively). Further, in MPTP treated monkeys, Karimi
et al. (2013) found a near perfect correlation (n= 16, r2= 0.95)
between striatal FDOPA K I values obtained in vivo with PET
and post-mortem striatal DA levels (measured using high perfor-
mance liquid chromatography with electrochemical detection). It
is likely, therefore, that individual differences in trait disinhibi-
tion are primarily related to individual differences in DA synthesis
capacity.
This interpretation is consistent with several other recent
findings on the neurobiology of impulse-control and addiction
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vulnerability. D2 autoreceptors located on DA nerve terminals
exert a negative feedback regulation that reduces DA synthe-
sis, DA neuron firing, and DA release (Wolf and Roth, 1990;
Zhu et al., 1992). Bello et al. (2011) generated mice defi-
cient in such D2 autoreceptors. These “autoDrd2KO” mice dis-
played elevated striatal DA synthesis and strikingly, demon-
strated increased sensitivity to the rewarding and psychomo-
tor stimulant properties of cocaine, together with a greatly
exaggerated motivation to work for food reward. I.e., height-
ened DA synthesis in the autoDrd2KO mice resulted in an
addiction-prone, disinhibited phenotype. In humans, striatal DA
synthesis capacity measured with [β-11C]DOPA PET is nega-
tively correlated with striatal D2 receptor density measured with
[11C]raclopride PET (Ito et al., 2011). Given that many pre-
synaptic D2 receptors in the striatum are DA autoreceptors (Sesack
et al., 1994), increased DA synthesis capacity in humans may
similarly reflect reduced D2 autoreceptor function. Notably, in
animal models, variation in trait impulsivity, measured by pre-
mature responding on a 5-choice serial reaction time test of
visual attention, has been linked to relatively reduced D2 recep-
tor levels in the VS, functioning as autoreceptors (Besson et al.,
2010).
Consistent with this, in humans, Buckholtz et al. (2010) (see
also Zald et al., 2008) recently found that trait non-planning
impulsivity was inversely correlated with D2/D3 autoreceptor
availability in the substantia nigra/ventral tegmental area, mea-
sured using [18F]fallypride PET. Furthermore, Van Leare et al.
(2009) found a selective negative correlation between cannabi-
noid CB1 receptor density, measured using [18F]MK-9470 PET,
in left hemisphere limbic regions and NS3 (Extravagance) scores
in healthy volunteers. Since CB1 receptor activation causes inhi-
bition of DA synthesis (Moranta et al., 2004), reduced density
of CB1 receptors would presumably result in higher levels of
DA synthesis, and the negative correlation between CB1 recep-
tor density and NS3 is consistent with the positive correlation
between ventral striatal DA synthesis capacity and NS3 seen
here.
Furthermore, Bello et al. (2011) found that autoDrd2KO
mice showed exaggerated phasic DA release, resulting from a
larger releasable pool of DA generated by the lack of DA syn-
thesis inhibition in DA terminals. Similarly, in both monkeys
(Doudet and Holden, 2003) and human individuals with PD
(Piccini et al., 2003), the magnitude of amphetamine-induced
striatal DA release as measured by [11C]-raclopride PET (an
indirect measure of phasic DA release, Grace, 2008), is pos-
itively correlated with DA synthesis capacity measured using
FDOPA PET. In humans, Buckholtz et al. (2010) found that
trait disinhibition predicted greater amph-induced DA release
(together with stronger drug-primed wanting) and the relation
between midbrain autoreceptor availability and trait impulsivity
was mediated via this enhanced amphetamine-induced striatal DA
release.
The influence of variation in DA synthesis capacity on EXT ten-
dency might result from DA’s established role in reward processing,
particularly the attribution of incentive salience (Berridge, 2007).
Incentive salience is a motivational component of reward, one that
transforms sensory information about rewards and reward cues
into attractive, “wanted” incentives, motivating pursuit (Berridge,
2007). Notably, in animals, there is considerable individual vari-
ability in incentive salience attribution, and rats with a strong
propensity to attribute incentive salience to reward cues also show
heightened behavioral disinhibition, risk-taking, and an increased
tendency to seek drugs like cocaine (Flagel et al., 2010). Available
data suggest that animals prone to attribute incentive salience to
reward cues have a more active DA system than those who do not
(Marinelli and White, 2000; Tomie et al., 2000). In healthy volun-
teers VS FDopa K I values have been found to positively correlate
with BOLD-fMRI activity to reward cues in brain regions linked
to incentive salience attribution (Siessmeier et al., 2006), and ven-
tral striatal BOLD-fMRI response to reward cues in humans is
increased as a function of trait non-planning impulsivity and is
linked to genetic variation in the D2 (auto)-receptor (Forbes et al.,
2009).
Of particular relevance to the development of extreme impulse
control problems following treatment with dopaminergic med-
ication in PD, rats with heightened incentive salience attribu-
tion show a greater propensity for dopaminergic drug-induced
sensitization – a form of neuroplasticity hypothesized to play
a key role in addiction (Flagel et al., 2008). In particular, the
incentive-sensitization theory (Robinson and Berridge, 2008)
posits that excessive drug use arises from the excessive attri-
bution of incentive salience to drug rewards and their cues,
due to progressive neuroadaptations in DA projections to ven-
tral striatal motivation circuitry. Strikingly, PD individuals with
DA dysregulation syndrome were shown to exhibit potenti-
ated l-DOPA-induced ventral striatal DA release, which corre-
lated with exaggerated drug-primed l-DOPA wanting, together
with enhanced responding to monetary reward (Evans et al.,
2006). Also, PD (and non-PD) individuals with disordered
gambling showed impaired DA D2 autoreceptor activity (Ray
et al., 2012) and exaggerated VS DA release to gambling and
other reward cues (O’Sullivan et al., 2011; see also Steeves
et al., 2009; Joutsa et al., 2012a), consistent with incentive-
sensitization.
It is possible that, rather than reflecting an underlying neu-
robiological risk factor for ICDs in PD, increased VS FDOPA
uptake could be the result of disease-related and/or drug-induced
neuroplastic changes leading to disease- and/or drug-induced dis-
inhibition. In the current sample of early-stage PD patients, who
had only recently begun DA replacement therapy, however, mean
ventral striatal FDOPA K I values were very similar to those of
healthy controls (Whone et al., 2004) and were unrelated to sever-
ity of PD. In animal models, there is some evidence that repeated
treatments with DA agonist drugs can enhance basal DA synthe-
sis in the VS (Rowlett et al., 1997) and frontal cortex (Chernoloz
et al., 2012). However, other studies show persistent inhibition
of DA synthesis following repeated treatment with DA agonists
(Imperato et al., 1996). A study of detoxified alcoholics found no
differences in VS DA synthesis capacity measured with FDOPA
PET (Heinz et al., 2005). Very recently, Joutsa et al. (2012b)
found increased medial orbitofrontal, but not ventral striatal,
FDOPA uptake in 10 individuals with manifest ICDs in PD. Since
disinhibitory traits were not measured in the patients or controls
of that study, however, it may be that several of the controls had
Frontiers in Psychology | Psychopathology February 2013 | Volume 4 | Article 90 | 6
Lawrence et al. Financial extravagance in Parkinson’s disease
high EXT risk, explaining the lack of difference in VS FDOPA
uptake between ICD cases and controls. Frontal, but not striatal,
DA synthesis is also increased following stress (Reinhard et al.,
1982), suggesting that enhanced frontal, but not ventral striatal,
FDOPA uptake in ICD cases may reflect state, as opposed to trait,
effects.
Furthermore, Giladi et al. (2007) and Bastiaens et al. (2013)
found that the appearance of heightened impulse control prob-
lems in affected PD individuals began only after a median interval
of ∼2 years of treatment, and our patients had only recently
been started on dopaminergic medication, within the previous
4–12 weeks, and were on only low doses of either l-DOPA or DA
agonist. In addition, Voon et al. (2007) found that NS scores were
not influenced by dopaminergic therapy. Importantly, numerous
studies have found a shared genetic diathesis to underlie associ-
ations between EXT disorders and traits related to disinhibition,
including NS (Young et al., 2000; Agrawal et al., 2004). Most criti-
cally, Derringer et al. (2010) found that genetic variation in DDC
activity predicted variation in trait disinhibition, suggesting that
variation in DDC activity reflects a trait EXT vulnerability, rather
than a disease or medication-related effect (see also Engeln et al.,
2012). Likewise, Flagel et al. (2010), found that, in rats, varia-
tion in incentive salience attribution and behavioral disinhibition
are genetically influenced, correlated traits that depend on ventral
striatal DA for their expression (Saunders and Robinson, 2012).
Hence, we think it highly unlikely that our findings of a posi-
tive correlation between levels of self-reported disinhibition and
VS DA synthesis capacity are a result of PD and its treatment with
dopaminergic medication. Rather, we think they reflect genetically
influenced, pre-existing neurobiological individual differences in
VS DA synthesis capacity in PD patients, underpinning variation
in trait disinhibition or EXT propensity, which in turn is associated
with future ICD morbidity risk (as PD advances and dopaminergic
drug therapy increases), resulting from an increased suscepti-
bility to DAergic-drug-induced incentive-sensitization (Boileau
et al., 2006). Longitudinal studies will be required to establish
the validity of this account.
In conclusion, we have shown that temperamental vulner-
ability to impulse control or EXT problems such as disor-
dered gambling in male PD patients is related to relatively
greater DA synthesis capacity in the ventral, but not dor-
sal, striatum. Our results are consistent with preclinical mod-
els of EXT risk, and may prove informative in understand-
ing the psychological and neurobiological mechanisms whereby
individual differences in temperament contribute to the devel-
opment of impulse control and addictive pathologies in the
context of the treatment of PD and other neurological disor-
ders.
ACKNOWLEDGMENTS
Support for this work was provided by Parkinson’s UK (grant ref.
G0603). We are most grateful to the technical PET staff for their
assistance, to Dr N. Pavese for assistance with Figure 1 and to all
the patients who participated in this study.
REFERENCES
Agrawal, A., Jacobson, K. C., Prescott, C.
A., and Kendler, K. S. (2004). A twin
study of personality and illicit drug
use and abuse/dependence. Twin
Res. 7, 72–81.
Agrawal, A., Lynskey, M. T., Todorov,
A. A., Schrage, A. J., Littlefield,
A. K., Grant, J. D., et al. (2011).
A candidate gene association study
of alcohol consumption in young
women. Alcohol Clin. Exp. Res. 35,
1–9.
Álvarez-Moya, E. M., Ochoa, C.,
Jiménez-Murcia, S., Aymamí, M.
N., Gómez-Peña, M., Fernández-
Aranda, F., et al. (2011). Effect of
executive functioning, decision-
making and self-reported
impulsivity on the treatment
outcome of pathologic gam-
bling. J. Psychiatry Neurosci. 36,
165–175.
Ando, J., Suzuki, A., Yamagata, S.,
Kijima, N., Maekawa, H., Ono, Y.,
et al. (2004). Genetic and envi-
ronmental structure of Cloninger’s
temperament and character
dimensions. J. Pers. Disord. 18,
379–393.
Bastiaens, J., Dorfman, B. J., Chris-
tos, B. J., and Nirenberg, M. J.
(2013). Prospective cohort study
of impulse control disorders in
Parkinson’s disease. Mov. Disord.
doi: 10.1002/mds.25291. [Epub
ahead of print].
Bello, E. P., Mateo, Y., Gelman, D. M.,
Noaín, D., Shin, J. H., Low, M. J.,
et al. (2011). Cocaine supersensi-
tivity and enhanced motivation for
reward in mice lacking dopamine
D2 autoreceptors. Nat. Neurosci. 14,
1033–1038.
Berridge, K. C. (2007). The debate over
dopamine’s role in reward: the case
for incentive salience. Psychophar-
macology (Berl.) 191, 391–431.
Besson, M., Belin, D., McNamara,
R., Theobold, D. E. H., Castel,
A., Beckett, V. L., et al. (2010).
Dissociable control of impulsivity
in rats by dopamine D2/3 recep-
tors in the core and shell sub-
regions of the nucleus accum-
bens. Neuropsychopharmacology 35,
560–569.
Bienfait, K. L., Menza, M., Mark, M.
H., and Dobkin, R. D. (2010).
Impulsive smoking in a patient
with Parkinson’s disease treated with
dopamine agonists. J. Clin. Neurosci.
17, 539–540.
Bjork, J. M., Knutson, B., and Hom-
mer, D. W. (2008). Incentive-elicited
striatal activation in adolescent chil-
dren of alcoholics. Addiction 103,
1308–1319.
Blanco, C., Myers, J., and Kendler,
K. S. (2012). Gambling, disor-
dered gambling and their associa-
tion with major depression and sub-
stance abuse: a web-based cohort
and twin-sibling study. Psychol. Med.
42, 497–508.
Boileau, I., Dagher, A., Leyton, M.,
Gunn, R. N., Baker, G. B., Diksic,
M., et al. (2006). Modelling sensiti-
zation to stimulants in humans: an
[11C]raclopride/position emission
tomography study in healthy men.
Arch. Gen. Psychiatry 63, 1386–1395.
Brooks, D. J. (2010). Imaging
approaches to Parkinson’s disease. J.
Nucl. Med. 51, 596–609.
Brown, W. D., Taylor, M. D., Roberts,
A. D., Oakes, T. R., Schueller, M.
J., Holden, J. E., et al. (1999).
FluoroDOPA PET shows the non-
dopaminergic as well as dopaminer-
gic destinations of levodopa. Neurol-
ogy 53, 1212–1218.
Buckholtz, J. W., Treadway, M. T.,
Cowan, R. L., Woodward, N. D.,
Li, R., Ansari, M. S., et al. (2010).
Dopaminergic network differences
in human impulsivity. Science 329,
532.
Chernoloz, O., El Mansari, M., and Blier,
P. (2012). Long-term administra-
tion of the dopamine D3/2 recep-
tor agonist pramipexole increases
dopamine and serotonin neuro-
transmission in the male rat fore-
brain. J. Psychiatry Neurosci. 37,
113–121.
Clark, L. A. (2005). Temperament as a
unifying basis for personality and
psychopathology. J. Abnorm. Psy-
chol. 114, 505–521.
Cloninger, C. R. (1987). A system-
atic method for clinical descrip-
tion and classification of personality
variants. Arch. Gen. Psychiatry 44,
573–588.
Dagher, A., and Robbins, T. W. (2009).
Personality, addiction, dopamine:
insights from Parkinson’s disease.
Neuron 61, 502–510.
Dalley, J. W., Everitt, B. J., and Rob-
bins, T. W. (2011). Impulsivity,
compulsivity, and top-down
cognitive control. Neuron 69,
680–694.
Derringer, J., Krueger, R. F., Dick,
D. M., Saccone, S., Grucza, R. A.,
Agrawal, A., et al. (2010). Pre-
dicting sensation seeking from
dopamine genes: a candidate-
system approach. Psychol. Sci. 21,
1282–1290.
Doudet, D. J., and Holden, J. E. (2003).
Raclopride studies of dopamine
release: dependence on presynap-
tic integrity. Biol. Psychiatry 54,
1193–1199.
www.frontiersin.org February 2013 | Volume 4 | Article 90 | 7
Lawrence et al. Financial extravagance in Parkinson’s disease
Ducci, F., Kaakinen, M., Pouta, A., Har-
tikainen, A.-L., Veijola, J., Isohanni,
M., et al. (2011). TTC12-ANKK1-
DRD2 and CHRNA5-CHRNA3-
CHRNB4 influence different path-
ways leading to smoking behavior
from adolescence to mid-adulthood.
Biol. Psychiatry 69, 650–660.
Eaton, N. R., Keyes, K. M., Krueger, R.
F., Balsis, S., Skodol, A. E., Markon,
K. E., et al. (2012). An invariant
dimensional liability model of gen-
der differences in mental disorder
prevalence: evidence from a national
sample. J. Abnorm. Psychol. 121,
282–288.
Elsworth, J. D., and Roth, R. H. (2009).
“Dopamine,” in Encyclopaedia of
Neuroscience, ed. L. R. Squire (Ams-
terdam: Elsevier), 539–547.
Engeln, M., Ahmed, S., Vouillac, C.,
Tison, F., Bezard, E., and Fernagut,
P.-O. (2012). Reinforcing proper-
ties of pramipexole in normal and
parkinsonian rats. Neurobiol. Dis.
49C, 79–86.
Ertan, F. S., Ertan, T., Kiziltan, G.,
and Uyguçgil, H. (2005). Relia-
bility and validity of the geri-
atric depression scale in depres-
sion in Parkinson’s disease. J.
Neurol. Neurosurg. Psychiatry 76,
1445–1447.
Evans, A. H., Lawrence, A. D., Potts,
J., Appel, S., and Lees, A. J. (2005).
Factors influencing susceptibility to
compulsive dopaminergic drug use
in Parkinson disease. Neurology 65,
1570–1574.
Evans, A. H., Pavese, N., Lawrence, A.
D., Tai, Y. F., Appel, S., Doder, M.,
et al. (2006). Compulsive drug use
linked to sensitized ventral striatal
dopamine transmission. Ann. Neu-
rol. 59, 852–858.
Flagel, S. B., Robinson, T. E., Clark, J. J.,
Clinton, S. M., Watson, S. J., Seeman,
P., et al. (2010). An animal model
of genetic vulnerability to behav-
ioral disinhibition and responsive-
ness to reward-related cues: impli-
cations for addiction. Neuropsy-
chopharmacology 35, 388–400.
Flagel, S. B., Watson, S. J., Akil, H.,
and Robinson, T. E. (2008). Indi-
vidual differences in the attribution
of incentive salience to a reward-
related cue: influence on cocaine
sensitization. Behav. Brain Res. 186,
48–56.
Flory, J. D., Harvey, P. D., Mitropoulou,
V., New, A. S., Silverman, J. M.,
Siever, L., et al. (2006). Dispositional
impulsivity in normal and abnor-
mal samples. J. Psychiatr. Res. 40,
438–447.
Forbes, E. E., Brown, S. M., Kimak, M.,
Ferrell, R. E., Manuck, S. B., and
Hariri, A. R. (2009). Genetic vari-
ation in components of dopamine
neurotransmission impacts ventral
striatal reactivity associated with
impulsivity. Mol. Psychiatry 14,
60–70.
Forbush, K. T., and Watson, D. (2013).
The structure of common and
uncommon mental disorders. Psy-
chol. Med. 43, 97–108.
Gallagher, D. A., O’Sullivan, S. S., Evans,
A. H., Lees, A. J., and Schrag,
A. (2007). Pathological gambling
in Parkinson’s disease: risk fac-
tors and differences from dopamine
dysregulation. An analysis of pub-
lished case series. Mov. Disord. 22,
1757–1763.
Giladi, N., Weitzman, N., Schreiber, S.,
Shabtai, H., and Peretz, C. (2007).
New onset heightened interest or
drive for gambling, shopping, eat-
ing or sexual activity in patients
with Parkinson’s disease: the role
of dopamine agonist treatment and
age at motor symptoms onset. J.
Psychopharmacol. 21, 501–506.
Grace, A. A. (2008). Physiology of
the normal and dopamine-depleted
basal ganglia: insights into levodopa
pharmacotherapy. Mov. Disord. 23,
S560–S569.
Hack, L. M., Kalsi, G., Aliev, F., Kuo, P.
H., Prescott, C. A., Patterson, D. G.,
et al. (2011). Limited associations of
dopamine system genes with alco-
hol dependence and related traits
in the Irish Affected Sib Pair Study
of Alcohol Dependence (IASPSAD).
Alcohol. Clin. Exp. Res. 35, 376–385.
Heinz,A., Siessmeier, T.,Wrase, J., Buch-
holz, H. G., Gründer, G., Kumakura,
Y., et al. (2005). Correlation of alco-
hol craving with striatal dopamine
synthesis capacity and D2/3 receptor
availability: a combined [18F]DOPA
and [18F]DMFP PET study in detox-
ified alcoholic patients. Am. J. Psy-
chiatry 162, 1515–1520.
Imperato, A., Obinu, M. C., Carta, G.,
Mascia, M. S., Casu, M. A., and
Gessa, G. L. (1996). Reduction of
dopamine release and synthesis by
repeated amphetamine treatment:
role in behavioral sensitization. Eur.
J. Pharmacol. 317, 231–237.
Ito, H., Kodaka, F., Takahashi, H.,
Takano, H., Arakawa, R., Shi-
mada, H., et al. (2011). Relation
between presynaptic and postsynap-
tic dopaminergic functions mea-
sured by positron emission tomog-
raphy: implications of dopaminergic
tone. J. Neurosci. 31, 7886–7890.
Joutsa, J., Johansson, J., Niemelä,
S., Ollikainen, A., Hirvonen, M.
M., Piepponen, P., et al. (2012a).
Mesolimbic dopamine release is
linked to symptom severity in patho-
logical gambling. Neuroimage 60,
1992–1999.
Joutsa, J., Martikainen, K., Niemelä, S.,
Johansson, J., Forsback, S., Rinne, J.
O., et al. (2012b). Increased medial
orbitofrontal [18F]fluorodopa
uptake in parkinsonian impulse
control disorders. Mov. Disord. 27,
778–782.
Kaasinen, V., Nurmi, E., Bergman, J.,
Eskola, O., Solin, O., Sonninen,
P., et al. (2001). Personality traits
and brain dopaminergic function in
Parkinson’s disease. Proc. Natl. Acad.
Sci. U.S.A. 98, 13272–13277.
Karimi, M., Tian, L., Brown, C. A., Flo-
res, H. P., Loftin, S. K., Videen, T. O.,
et al. (2013). Validation of nigros-
triatal PET measures: critical limits.
Ann. Neurol. doi:10.1002/ana.23798.
[Epub ahead of print].
Kessler, R. C., Hwang, I., LaBrie, R.,
Petukhova, M., Sampson, N. A.,
Winters, K. C., et al. (2008). DSM-
IV pathological gambling in the
national comorbidity survey replica-
tion. Psychol. Med. 38, 1351–1360.
Khan, A. A., Jacobson, K. C., Gardner, C.
O., Prescott, C. A., and Kendler, K. S.
(2005). Personality and comorbid-
ity of common psychiatric disorders.
Br. J. Psychiatry 186, 190–196.
Kish, S. J., Shannak, K., and
Hornykiewicz, O. (1988). Uneven
pattern of dopamine loss in the
striatum of patients with idiopathic
Parkinson’s disease: pathophysio-
logic and clinical implications. N.
Engl. J. Med. 318, 876–880.
Kristjansson, S. D., Agrawal, A., Lessov-
Schlaggar, C. N., Madden, P. A.,
Cooper, M. L., Bucholz, K. K., et
al. (2012). The relationship between
rs3779084 in the dopa decarboxy-
lase (DDC) gene and alcohol con-
sumption is mediated by drinking
motives in regular smokers. Alcohol.
Clin. Exp. Res. 36, 162–170.
Krueger, R. F., Markon, K. E., Patrick,
C. J., Benning, S. D., and Kramer, M.
D. (2007). Linking antisocial behav-
ior, substance use, and personality:
an integrative quantitative model of
the adult externalizing spectrum. J.
Abnorm. Psychol. 116, 645–666.
Krueger, R. F., and South, S. C. (2009).
Externalizing disorders: cluster 5
of the proposed meta-structure for
DSM-V and ICD-11. Psychol. Med.
39, 2061–2070.
Kumakura, Y., and Cumming, P. (2009).
PET studies of cerebral levodopa
metabolism: a review of clinical
findings and modelling approaches.
Neuroscientist 15, 635–650.
Laakso, A., Pohjalainen, T., Bergman, J.,
Kajander, J., Haaparanta, M., Solin,
O., et al. (2005). The A1 allele of the
human D2 dopamine receptor gene
is associated with increased activity
of striatal l-amino acid decarboxy-
lase in healthy subjects. Pharmacoge-
netics 15, 387–391.
Laakso, A., Vilkman, H., Bergman, J.,
Haaparanta, M., Solin, O., Syvälahti,
E., et al. (2002). Sex differences in
striatal presynaptic dopamine syn-
thesis capacity in healthy subjects.
Biol. Psychiatry 52, 759–763.
Lawrence, A. D., Evans, A. H., and
Lees, A. J. (2003). Compulsive use
of dopamine replacement therapy
in Parkinson’s disease: reward sys-
tems gone awry? Lancet Neurol. 2,
595–604.
Lind, P. A., Zhu, G., Montgomery, G. W.,
Madden, P. A., Heath, A. C., Mar-
tin, N. G., et al. (2012). Genome-
wide association study of a quan-
titative disordered gambling trait.
Addict. Biol. doi: 10.1111/j.1369-
1600.2012.00463.x. [Epub ahead of
print].
Ma, J. Z., Beuten, J., Payne, T. J., Dupont,
R. T., Elston, R. C., and Li, M.
D. (2005). Haplotype analysis indi-
cates an association between the
DOPA decarboxylase (DDC) gene
and nicotine dependence. Hum. Mol.
Genet. 14, 1691–1698.
MacLaren, V. V., Fugelsang, J. A.,
Harrigan, K. A., and Dixon, M.
J. (2011). The personality of
pathological gamblers: a meta-
analysis. Clin. Psychol. Rev. 31,
1057–1067.
Marinelli, M., and White, F. J. (2000).
Enhanced vulnerability to cocaine
self-administration is associated
with elevated impulse activity of
midbrain dopamine neurons. J.
Neurosci. 20, 8876–8885.
Markon, K. E., Krueger, R. F., and
Watson, D. (2005). Delineating the
structure of normal and abnormal
personality: an integrative hierarchi-
cal approach. J. Pers. Soc. Psychol. 88,
139–157.
Miyazaki, K., Miyazaki, K. W., and Doya,
K. (2011). Activation of dorsal raphe
serotonin neurons underlies waiting
for delayed rewards. J. Neurosci. 31,
469–479.
Moore, R. Y., Whone, A. L., and
Brooks, D. J. (2008). Extrastri-
atal monoamine neuron function
in Parkinson’s disease: an 18F-
dopa PET study. Neurobiol. Dis. 29,
381–390.
Moore, R. Y., Whone, A. L., McGowan,
S., and Brooks, D. J. (2003).
Monoamine neuron innervation of
the normal human brain: an 18F-
DOPA PET study. Brain Res. 982,
137–145.
Frontiers in Psychology | Psychopathology February 2013 | Volume 4 | Article 90 | 8
Lawrence et al. Financial extravagance in Parkinson’s disease
Moranta, D., Esteban, S., and García-
Sevilla, J. A. (2004). Differential
effects of acute cannabinoid drug
treatment, mediated by CB1 recep-
tors, on the in vivo activity of tyro-
sine and tryptophan hydroxylase in
the rat brain. Naunyn Schmiedebergs
Arch. Pharmacol. 369, 516–524.
Oleski, J., Cox, B. J., Clara, I., and
Hills, A. (2011). Pathological gam-
bling and the structure of common
mental disorders. J. Nerv. Ment. Dis.
199, 956–960.
O’Sullivan, S., Djamshidian, A., Ahmed,
Z., Evans, A. H., Lawrence, A. D.,
Holton, J. L., et al. (2010). Impulsive-
compulsive spectrum behaviours in
pathologically confirmed progres-
sive supranuclear palsy. Mov. Disord.
25, 638–642.
O’Sullivan, S. S., Wu, K., Politis, M.,
Lawrence, A. D., Evans, A. H., Bose,
S. K., et al. (2011). Cue-induced stri-
atal dopamine release in Parkinson’s
disease associated impulse control
disorders. Brain 134, 969–978.
Patlak, C. S., and Blasberg, R. G.
(1985). Graphical evaluation of
blood-to-brain transfer constants
from multiple-time uptake data.
Generalizations. J. Cereb. Blood Flow
Metab. 5, 584–590.
Pavese, N., Simpson, B. S., Metta, V.,
Ramlackhansingh, A., Chaudhuri,
K. R., and Brooks, D. J. (2012).
[(18)F]FDOPA uptake in the raphe
nuclei complex reflects serotonin
transporter availability. A combined
[(18F)]FDOPA and [(11)C]DASB
PET study in Parkinson’s disease.
Neuroimage 59, 1080–1084.
Piccini, P., Pavese, N., and Brooks, D.
J. (2003). Endogenous dopamine
release after pharmacological chal-
lenge in Parkinson’s disease. Ann.
Neurol. 53, 647–653.
Pickering, A. D., and Gray, J. A. (1999).
“The neuroscience of personality,” in
Handbook of Personality: Theory and
Research, 2nd Edn, eds L. A. Per-
vin and O. P. John (New York: The
Guilford Press), 277–299.
Pine, A., Shiner, T., Seymour, B., and
Dolan, R. J. (2010). Dopamine, time
and impulsivity in humans. J. Neu-
rosci. 30, 8888–8896.
Pitzer, M., Esser, G., Schmidt, M. H., and
Laucht, M. (2007). Temperament in
the developmental course: a longitu-
dinal comparison of New York lon-
gitudinal study-derived dimensions
with the junior temperament and
character inventory. Compr. Psychi-
atry 48, 572–582.
Ray, N., Miyasaki, J. M., Zurowski,
M., Ko, J. H., Cho, S. S., Lang,
A. E., et al. (2012). Extrastriatal
dopaminergic abnormalities of DA
homeostasis in Parkinson’s patients
with medication-induced patholog-
ical gambling: a [11C] FLB-457
and PET study. Neurobiol. Dis. 48,
519–525.
Reinhard, J. F. Jr., Bannon, M. J.,
and Roth, R. H. (1982). Accelera-
tion by stress of dopamine synthesis
and metabolism in prefrontal cortex:
antagonism by diazepam. Naunyn
Schmiedebergs Arch. Pharmacol. 318,
374–377.
Robinson, T. E., and Berridge, K. C.
(2008). The incentive sensitization
theory of addiction: some current
issues. Philos. Trans. R. Soc. Lond. B.
Biol. Sci. 363, 3137–3146.
Rowlett, J. K., Mattingly, B. A., and
Bardo, M. T. (1997). Locomotor
activity and dopamine synthesis fol-
lowing 1 and 15 days of withdrawal
from repeated apomorphine treat-
ments. Pharmacol. Biochem. Behav.
57, 13–18.
Salokangas, R. K., Vilkman, H., Ilonen,
T., Taiminen, T., Bergman, J., Haa-
paranta, M., et al. (2000). High lev-
els of dopamine activity in the basal
ganglia of cigarette smokers. Am. J.
Psychiatry 157, 632–634.
Saunders, B. T., and Robinson, T. E.
(2012). The role of dopamine in the
accumbens core in the expression
of pavlovian-conditioned responses.
Eur. J. Neurosci. 36, 2521–2532.
Schlagenhauf, F., Rapp, M. A., Huys,
Q. J., Beck, A., Wüstenberg, T.,
Deserno, L., et al. (2012). Ven-
tral striatal prediction error signal-
ing is associated with dopamine
synthesis capacity and fluid intel-
ligence. Hum. Brain. Mapp. doi:
10.1002/hbm.22000. [Epub ahead of
print].
Sesack, S. R., Aoki, C., and Pickel, V. M.
(1994). Ultrastructural localization
of D2 receptor-like immunoreactiv-
ity in midbrain dopamine neurons
and their striatal targets. J. Neurosci.
14, 88–106.
Sher, K. J., Bartholow, B. D., and Wood,
M. D. (2000). Personality and sub-
stance use disorders: a prospective
study. J. Consult. Clin. Psychol. 68,
818–829.
Sher, K. J., and Trull, T. J. (1994).
Personality and disinhibitory psy-
chopathology: alcoholism and
antisocial personality disorder. J.
Abnorm. Psychol. 103, 92–102.
Siessmeier, T., Kienast, T., Wrase, J.,
Larsen, J. L., Braus, D. F., Smolka, M.
N., et al. (2006). Net influx of plasma
6-[18F]fluoro-l-DOPA (FDOPA)
to the ventral striatum correlates
with prefrontal processing of affec-
tive stimuli. Eur. J. Neurosci. 24,
305–313.
Slutske, W. S., Cho, S. B., Piasecki, T. M.,
and Martin, N. G. (2013). Genetic
overlap between personality and risk
for disordered gambling: evidence
from a national community-based
Australian twin study. J. Abnorm.
Psychol. 122, 50–55.
Slutske, W. S., Moffitt, T. E., Poulton,
R., and Caspi, A. (2012). Under-
controlled temperament at age 3
predicts disordered gambling at age
32: a longitudinal study of a com-
plete birth cohort. Psychol. Sci. 23,
510–516.
Snow, B. J., Tooyama, I., McGeer,
E. G., Yamada, T., Calne, D.
B., Takahashi, H., et al. (1993).
Human positron emission tomo-
graphic [18F]fluorodopa studies
correlate with dopamine cell counts
and levels. Ann. Neurol. 34, 324–330.
Spinks, T. J., Jones, T., Bloomfield, P. M.,
Bailey, D. L., Miller, M., Hogg, D.,
et al. (2000). Physical characteristics
of the ECAT EXACT 3D positron
tomograph. Phys. Med. Biol. 45,
2601–2261.
Stallings, M. C., Hewitt, J. K., Cloninger,
C. R., Heath, A. C., and Eaves,
L. J. (1996). Genetic and environ-
mental structure of the tridimen-
sional personality questionnaire:
three or four temperament dimen-
sions? J. Pers. Soc. Psychol. 70,
127–140.
Steeves, T. D. L., Miyasaki, J., Zurowski,
M., Lang, A. E., Pellecchia, G., Van
Eimeren, T., et al. (2009). Increased
striatal dopamine release in Parkin-
sonian patients with pathological
gambling: a [11C] raclopride PET
study. Brain 132, 1376–1385.
Takeuchi, M., Miyaoka, H., Tomoda,
A., Suzuki, M., Lu, X., and Kita-
mura, T. (2011). Validity and relia-
bility of the Japanese version of the
temperament and character inven-
tory: a study of university and col-
lege students. Compr. Psychiatry 52,
109–117.
Tiihonen, J., Vilkman, H., Rasanen,
P., Ryynanen, O.-P., Hakko, H.,
Bergman, J., et al. (1998). Striatal
presynaptic dopamine function in
type 1 alcoholics measured with
positron emission tomography. Mol.
Psychiatry 4, 156–161.
Tison, F., Normand, E., Jaber, M.,
Aubert, I., and Bloch, B. (1991). Aro-
matic l-amino-acid decarboxylase
(DOPA decarboxylase) gene expres-
sion in dopaminergic and seroton-
ergic cells of the rat brainstem. Neu-
rosci. Lett. 127, 203–206.
Tomie, A., Aguado, A. S., Pohorecky,
L. A., and Benjamin, D. (2000).
Individual differences in Pavlov-
ian autoshaping of lever pressing
in rats predict stress-induced cor-
ticosterone release and mesolimbic
levels of monoamines. Pharmacol.
Biochem. Behav. 65, 509–517.
Van Leare, K., Goffin, K., Bormans,
G., Casteels, C., Mortelmans, L., de
Hoon, J., et al. (2009). Relation-
ship of type 1 cannabinoid receptor
availability in the human brain to
novelty-seeking temperament. Arch.
Gen. Psychiatry 66, 196–204.
Voon, V., Schoerling, A., Wenzel, S.,
Ekanayake, V., Reiff, J., Trenkwalder,
C., et al. (2011a). Frequency of
impulse control behaviours associ-
ated with dopaminergic therapy in
restless legs syndrome. BMC Neu-
rol. 11:117. doi:10.1186/1471-2377-
11-117
Voon, V., Sohr, M., Lang, A. E., Potenza,
M. N., Siderowf, A. D., Whetteckey,
J., et al. (2011b). Impulse control
disorders in Parkinson’s disease: a
multicenter case-control study. Ann.
Neurol. 69, 986–996.
Voon, V., Thomsen, T., Miyasaki, J. M.,
de Souza, M., Shafro, A., Fox, S. H.,
et al. (2007). Factors associated with
dopaminergic drug-related patho-
logical gambling in Parkinson dis-
ease. Arch. Neurol. 64, 212–216.
Weintraub, D., Papay, K., and Siderowf,
A. (2013). Screening for impulse
control symptoms in patients with
de novo Parkinson disease: a
case-control study. Neurology 80,
176–180.
Weintraub, D., Sohr, M., Potenza, M. N.,
Siderowf, A. D., Stacy, M., Voon, V.,
et al. (2010). Impulse control disor-
ders in Parkinson’s disease: a cross-
sectional study of 3090 patients.
Arch. Neurol. 67, 589–595.
Whone, A. L., Bailey, D. L., Remy, P.,
Pavese, N., and Brooks, D. J. (2004).
A technique for standardized central
analysis of 6-18F-Fluoro-l-DOPA
PET data from a multicenter study.
J. Nucl. Med. 45, 1135–1145.
Whone, A. L., Moore, R. Y., Piccini, P.
P., and Brooks, D. J. (2003a). Plas-
ticity of the nigropallidal pathway in
Parkinson’s disease. Ann. Neurol. 53,
206–213.
Whone, A. L., Watts, R. L., Stoessl, A.
J., Davis, M., Reske, S., Nahmias, C.,
et al. (2003b). Slower progression
of Parkinson’s disease with ropini-
role versus levodopa: the REAL-PET
study. Ann. Neurol. 54, 93–101.
Winstanley, C. A., Theobald, D. E.,
Dalley, J. W., and Robbins, T. W.
(2005). Interactions between sero-
tonin and dopamine in the con-
trol of impulsive choice in rats:
therapeutic implications for impulse
control disorders. Neuropsychophar-
macology 30, 669–682.
www.frontiersin.org February 2013 | Volume 4 | Article 90 | 9
Lawrence et al. Financial extravagance in Parkinson’s disease
Wolf, M. E., and Roth, R. H.
(1990). Autoreceptor regulation of
dopamine synthesis. Ann. N. Y. Acad.
Sci. 604, 323–343.
Yau, W.-Y. W., Zubieta, J.-K., Weiland,
B. J., Samudra, P. G., Zucker, R. A.,
and Heitzeg, M. M. (2012). Nucleus
accumbens response to incentive
stimuli anticipation in children of
alcoholics: relationships with pre-
cursive behavioral risk and life-
time alcohol use. J. Neurosci. 32,
2544–2551.
Young, S. E., Stallings, M. C., Corley,
R. P., Krauter, K. S., and Hewitt,
J. K. (2000). Genetic and envi-
ronmental influences on behavioral
disinhibition. Am. J. Med. Genet. B.
Neuropsychiatr. Genet. 96, 684–695.
Yu, Y., Panhuysen, C., Kranzler, H.
R., Hesselbrock, V., Rounsaville, B.,
Weiss, R., et al. (2006). Intronic
variants in the dopa decarboxylase
(DDC) gene are associated with
smoking behaviour in European-
Americans and African-Americans.
Hum. Mol. Genet. 15, 2192–2199.
Zald, D. H., Cowan, R. L., Riccardi,
P., Baldwin, R. M., Ansari, M.
S., Li, R., et al. (2008). Midbrain
dopamine receptor availability is
inversely associated with novelty-
seeking traits in humans. J. Neurosci.
14372–14378.
Zhang, P., Ye, Y., Wang, X., Gelern-
ter, J., Mai, J. Z., and Li, M.
D. (2006). DOPA decarboxylase
gene is associated with nicotine
dependence. Pharmacogenomics 7,
1159–1166.
Zhu, M. Y., Juorio, A. V., Paterson, I.
A., and Boulton, A. A. (1992). Reg-
ulation of aromatic l-amino acid
decarboxylase by dopamine recep-
tors in the rat brain. J. Neurochem.
58, 636–641.
Conflict of Interest Statement: The
authors declare that the research was
conducted in the absence of any com-
mercial or financial relationships that
could be construed as a potential con-
flict of interest.
Received: 28 September 2012; accepted:
07 February 2013; published online: 27
February 2013.
Citation: Lawrence AD, Brooks DJ
and Whone AL (2013) Ventral stri-
atal dopamine synthesis capacity pre-
dicts financial extravagance in Parkin-
son’s disease. Front. Psychol. 4:90. doi:
10.3389/fpsyg.2013.00090
This article was submitted to Frontiers in
Psychopathology, a specialty of Frontiers
in Psychology.
Copyright © 2013 Lawrence, Brooks and
Whone. This is an open-access article dis-
tributed under the terms of the Creative
Commons Attribution License, which
permits use, distribution and reproduc-
tion in other forums, provided the orig-
inal authors and source are credited
and subject to any copyright notices
concerning any third-party graphics
etc.
Frontiers in Psychology | Psychopathology February 2013 | Volume 4 | Article 90 | 10
